Hope Rugo
Hope Rugo
Verified email at
Cited by
Cited by
Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer
J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ...
New England Journal of Medicine 366 (6), 520-529, 2012
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ...
New England Journal of Medicine 379 (22), 2108-2121, 2018
Palbociclib and letrozole in advanced breast cancer
RS Finn, M Martin, HS Rugo, S Jones, SA Im, K Gelmon, N Harbeck, ...
New England journal of medicine 375 (20), 1925-1936, 2016
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK Marcom, ...
Journal of clinical oncology 23 (4), 792-799, 2005
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy
DG DeNardo, DJ Brennan, E Rexhepaj, B Ruffell, SL Shiao, SF Madden, ...
Cancer discovery 1 (1), 54-67, 2011
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ...
New England Journal of Medicine 380 (20), 1929-1940, 2019
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
JK Litton, HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, ...
New England Journal of Medicine 379 (8), 753-763, 2018
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
KL Blackwell, HJ Burstein, AM Storniolo, H Rugo, G Sledge, M Koehler, ...
Journal of clinical oncology 28 (7), 1124-1130, 2010
4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)
F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ...
Annals of Oncology 29 (8), 1634-1657, 2018
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo …
PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ...
The Lancet 390 (10105), 1833-1842, 2017
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer
J Baselga, V Semiglazov, P Van Dam, A Manikhas, M Bellet, ...
Journal of Clinical Oncology 27 (16), 2630-2637, 2009
3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3)
F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ...
The Breast 31, 244-259, 2017
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F Andre, CH Barrios, ...
The Breast 23 (5), 489-502, 2014
Breast cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
AE Giuliano, JL Connolly, SB Edge, EA Mittendorf, HS Rugo, LJ Solin, ...
CA: a cancer journal for clinicians 67 (4), 290-303, 2017
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2 …
HA Burris, HS Rugo, SJ Vukelja, CL Vogel, RA Borson, S Limentani, ...
Journal of Clinical Oncology 29 (4), 398-405, 2011
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells
B Ruffell, D Chang-Strachan, V Chan, A Rosenbusch, CMT Ho, N Pryer, ...
Cancer cell 26 (5), 623-637, 2014
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast CancerBicalutamide in AR (+) ER/PgR (−) Metastatic …
A Gucalp, S Tolaney, SJ Isakoff, JN Ingle, MC Liu, LA Carey, K Blackwell, ...
Clinical cancer research 19 (19), 5505-5512, 2013
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: final …
KL Blackwell, HJ Burstein, AM Storniolo, HS Rugo, G Sledge, G Aktan, ...
Journal of Clinical Oncology 30 (21), 2585-2592, 2012
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ...
New England Journal of Medicine 372 (2), 134-141, 2015
NCCN Practice Guidelines for Cancer-Related Fatigue.
V Mock, A Atkinson, A Barsevick, D Cella, B Cimprich, C Cleeland, ...
Oncology (Williston Park, NY) 14 (11A), 151-161, 2000
The system can't perform the operation now. Try again later.
Articles 1–20